Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Accelerate Diagnosti (AXDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 741,998
  • Shares Outstanding, K 54,200
  • Annual Sales, $ -66,140 K
  • Annual Income, $ 125,600 K
  • 36-Month Beta 2.48
  • Price/Sales 184.64
  • Price/Cash Flow N/A
  • Price/Book 9.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.39
  • Low Estimate -0.43
  • Prior Year -0.27
  • Growth Rate Est. (year over year) -51.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.70 +13.23%
on 11/20/18
15.29 -5.95%
on 12/03/18
-0.11 (-0.76%)
since 11/12/18
3-Month
12.70 +13.23%
on 11/20/18
23.71 -39.35%
on 09/25/18
-6.97 (-32.65%)
since 09/12/18
52-Week
12.70 +13.23%
on 11/20/18
30.35 -52.62%
on 01/26/18
-15.62 (-52.07%)
since 12/12/17

Most Recent Stories

More News
Accelerate Diagn is Among the Companies in the Life Sciences Tools & Services Industry with the Best Relative Performance (AXDX , PACB , PRAH , CRL , A )

We looked at the Life Sciences Tools & Services industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength....

AXDX : 14.44 (+5.48%)
PACB : 7.55 (+0.67%)
PRAH : 106.13 (+2.05%)
Relatively Good Performance Detected in Shares of Accelerate Diagn in the Life Sciences Tools & Services Industry (AXDX , PRAH , ILMN , PKI , A )

Below are the top five companies in the Life Sciences Tools & Services industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks...

AXDX : 14.44 (+5.48%)
ILMN : 341.43 (+3.81%)
PRAH : 106.13 (+2.05%)
Accelerate Diagnostics Pledges Matching Support for Sepsis Alliance #GivingTuesday Movement to Raise Awareness of Sepsis as a Medical Emergency

Accelerate Diagnostics, Inc. has joined with Sepsis Alliance to celebrate #GivingTuesday, November 27th, a global day of giving that harnesses the collective power of individuals, communities and organizations...

AXDX : 14.44 (+5.48%)
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

AXDX : 14.44 (+5.48%)
Accelerate Diagnostics: 3Q Earnings Snapshot

TUCSON, Ariz. (AP) _ Accelerate Diagnostics Inc. (AXDX) on Tuesday reported a loss of $22.1 million in its third quarter.

AXDX : 14.44 (+5.48%)
Accelerate Diagnostics reports Q3 2018 financial results

Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and...

AXDX : 14.44 (+5.48%)
Relatively Good Performance Detected in Shares of Luminex Corp in the Life Sciences Tools & Services Industry (LMNX , ILMN , AXDX , BRKR , PKI )

Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...

AXDX : 14.44 (+5.48%)
ILMN : 341.43 (+3.81%)
LMNX : 27.52 (+3.97%)
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline

Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXDX : 14.44 (+5.48%)
Shares of Neogenomics Inc Rank the Highest in Terms of Relative Performance in the Life Sciences Tools & Services Industry (NEO , AXDX , BRKR , CBM , A )

Here are the top 5 stocks in the Life Sciences Tools & Services industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were...

AXDX : 14.44 (+5.48%)
BRKR : 32.09 (+2.39%)
NEO : 13.67 (-1.44%)
Accelerate Diagn Has Returned 22.9% Since SmarTrend Recommendation (AXDX)

SmarTrend identified a Downtrend for Accelerate Diagn (NASDAQ:AXDX) on October 3rd, 2018 at $20.26. In approximately 3 weeks, Accelerate Diagn has returned 22.93% as of today's recent price of $15.61....

AXDX : 14.44 (+5.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AXDX with:

Business Summary

Accelerate Diagnostics, Inc. is focused on developing and commercializing instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The company is developing BACcel(TM) system, a rapid diagnostic platform for diagnosis in life-threatening bacterial infections...

See More

Key Turning Points

2nd Resistance Point 14.80
1st Resistance Point 14.25
Last Price 14.44
1st Support Level 13.39
2nd Support Level 13.08

See More

52-Week High 30.35
Fibonacci 61.8% 23.61
Fibonacci 50% 21.52
Fibonacci 38.2% 19.44
Last Price 14.44
52-Week Low 12.70

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar